The Pharmacy Times® Infectious Disease Resource Center is a comprehensive resource for clinical news and expert insights on a group of disorders caused by organisms, such as bacteria, viruses, fungi, or parasites.
September 17th 2025
Travelers face rising infectious disease risks, including measles, chikungunya, chagas disease, and others.
The Importance of Outpatient Stewardship for Health System Pharmacists
December 10th 2019Lisa Dumkow, PharmD, BCIDP, a clinical pharmacist of antimicrobial stewardship, discusses outpatient stewardship and why it's vital for health system pharmacists. This video was filmed at the 2019 ASHP Midyear Meeting Clinical Meeting & Exhibition in Las Vegas.
Watch
New Treatment for CABP Receives FDA Approval
October 25th 2019Officials with the FDA have expanded the use of Melinta Therapeutics’ delafloxacin (Baxdela) to include treatment of adult patients with community-acquired bacterial pneumonia caused by designated susceptible bacteria, but the drug’s availability will be delayed for this new indication.
Read More
Treatment for C difficile Shows Promising Potential in First-in-Human Phase 1 Trial
October 6th 2019A first-in-human trial evaluating the safety, pharmacokinetics, and fecal microbiome effects of a novel DNA polIIIC inhibitor demonstrated the antibacterial’s promise as a potential treatment alternative to vancomycin for the treatment of Clostridioides difficile.
Read More
Updated CAP Guidelines Narrows the Scope
October 3rd 2019The newly published guidelines answer 16 core questions about the diagnosis and treatment of CAP in adults. The guidelines are more narrow in scope than previous versions and focus primarily on the care of a patient with active pneumonia.
Read More
Risks of Rocky Mountain Spotted Fever Examined
July 18th 2019A binational team of investigators at the University of California, Davis, has conducted the first comprehensive study to examine the risk factors for Rocky Mountain spotted fever in Mexicali, Mexico. They found that citywide, just 1 in 1000 ticks was infected with the disease, but in certain neighborhoods, about 1 in 10 ticks was infected.
Read More
Robust Responses Found in 20-Serotype Pneumococcal Vaccine Trial
April 17th 2019The study presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, Netherlands was a phase 2 randomized, active-controlled, double-blinded trial (N=444). All participants were ages 60 to 64 years.
Read More
FDA OKs Treatment for Community-Acquired Bacterial Pneumonia and Skin Infections
October 4th 2018FDA officials have approved omadacycline (Nuzyra, Paratek), a modernized tetracycline, to treat adults with acute skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
Read More
Study: Adult Vaccination Increases With Health Insurers' Pharmacy Benefit
September 25th 2018Inconsistency of insurance policy coverage, unaffordability, and difficulty accessing vaccine providers were found to be key barriers for adult immunization in a recent study by UCLA Center for Health Policy researchers.
Read More